Orelabrutinib with chemotherapy for a subtype of large B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called orelabrutinib given with standard chemotherapy for a specific subtype of diffuse large B-cell lymphoma (DLBCL) called MCD. The treatment aims to improve outcomes and is followed by a maintenance phase with orelabrutinib alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of MCD subtype DLBCL (a specific genetic type) that has not been treated before.
- Your kidney and liver function must be within acceptable levels.
- You must not be pregnant or breastfeeding, and if you could become pregnant, you must agree to use contraception.
- You must not have had a stroke or bleeding in the past 6 months, and you must not be taking certain medications that interact with the study drug.
- You must not have active hepatitis or other autoimmune diseases, and you must not have had an organ transplant or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
This trial tests a new combination of drugs for people newly diagnosed with an aggressive type of lymphoma called diffuse large B-cell lymphoma (DLBCL). The combo includes orelabrutinib plus standard chemo-immunotherapy, and may help improve outcomes for those at intermediate or high risk.
This trial tests a combination of targeted therapy (Orelabrutinib) plus standard chemotherapy (Pola-R-CHP) for people with untreated non-GCB diffuse large B-cell lymphoma. The goal is to see if this new mix works better than the usual treatment.
This trial tests whether adding a targeted therapy called orelabrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of fast-growing lymphoma (CD5-positive DLBCL). If you have this lymphoma and haven't had a BTK inhibitor before, this combination might work better than chemo alone.
This trial tests a new targeted drug (orelabrutinib) with or without another drug that targets CD20 (a protein on some immune cells) for people with untreated marginal zone lymphoma. It aims to see if this combination works better than other treatments and may be an option for those who cannot have radiation.
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.